Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo

Blood

Volumn 116, Issue 23, 2010, Pages 4926-4933

  Kasama, Yuri ^a   Sekiguchi, Satoshi ^b   Saito, Makoto ^a   Tanaka, Kousuke ^a   Satoh, Masaaki ^a   Kuwahara, Kazuhiko ^a   Sakaguchi, Nobuo ^a   Takeya, Motohiro ^a   Hiasa, Yoichi ^c   Kohara, Michinori ^b   Tsukiyama Kohara, Kyoko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BASIC FIBROBLAST GROWTH FACTOR; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; KERATINOCYTE DERIVED CHEMOKINE; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HEPATITIS C VIRUS; IN VIVO STUDY; LARGE CELL LYMPHOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; VIRUS GENOME;

EID: 78649736831     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-05-283358     Document Type: Article

References (46)

1. Ferri C, Monti M, La Civita L, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood. 1993;82(12):3701-3704. (Pubitemid 24006053)
2. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A. 1990;87(17):6547-6549. (Pubitemid 20351517)
3. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis.Acase- control study. Ann Intern Med. 1992;116(2):97-102.
4. Silvestri F, Pipan C, Barillari G, et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood. 1996;87(10):4296-4301.
5. Ascoli V, Lo Coco F, Artini M, Levrero M, Martelli M, Negro F. Extranodal lymphomas associated with hepatitis C virus infection. Am J Clin Pathol. 1998;109(5):600-609.
6. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003;102(3):996-999.
7. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and overt B-cell malignancy. Semin Liver Dis. 2000;20(2):143-157.
8. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin's lymphoma: systematic review and meta-analysis. Gastroenterology. 2003;125(6):1723-1732. (Pubitemid 37500437)
9. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer. 2004;111(1):1-8. (Pubitemid 38859276)
10. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science. 1998;282(5390):938-941.
11. Rosa D, Saletti G, De Gregorio E, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A. 2005;102(51):18544-18549.
12. Wakita T, Taya C, Katsume A, et al. Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J Biol Chem. 1998;273(15):9001-9006.
13. Machida K, Tsukiyama-Kohara K, Seike E, et al. Inhibition of cytochrome c release in Fas-mediated signaling pathway in transgenic mice induced to express hepatitis C viral proteins. J Biol Chem. 2001;276(15):12140-12146.
14. Machida K, Tsukiyama-Kohara K, Sekiguch S, et al. Hepatitis C virus and disrupted interferon signaling promote lymphoproliferation via type II CD95 and interleukins. Gastroenterology. 2009;137(1):285-296,296 e281-211.
15. Lerat H, Rumin S, Habersetzer F, et al. In vivo tropism of hepatitis C virus genomic sequences in hematopoietic cells: influence of viral load, viral genotype, and cell phenotype. Blood. 1998;91(10):3841-3849.
16. Karavattathayyil SJ, Kalkeri G, Liu HJ, et al. Detection of hepatitis C virus RNA sequences in Bcell non-Hodgkin lymphoma. Am J Clin Pathol. 2000;113(3):391-398.
17. Rickert RC, Roes J, Rajewsky K. B lymphocyte-specific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 1997;25(6):1317-1318.
18. Tanaka T, Lau JY, Mizokami M, et al. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J Hepatol. 1995;23(6):742-745.
19. Tsukiyama-Kohara K, Tone S, Maruyama I, et al. Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells. J Biol Chem. 2004;279(15):14531-14541.
20. Nishimura T, Kohara M, Izumi K, et al. Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase. J Biol Chem. 2009;284(52):36442-36452.
21. Tsukiyama-Kohara K, Poulin F, Kohara M, et al. Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1. Nat Med. 2001;7(10):1128-1132.
22. Fujimura S, Xing Y, Takeya M, et al. Increased expression of germinal center-associated nuclear protein RNA-primase is associated with lymphomagenesis. Cancer Res. 2005;65(13):5925-5934.
23. Miyazaki T, Kato I, Takeshita S, Karasuyama H, Kudo A. Lambda5 is required for rearrangement of the Ig kappa light chain gene in pro-B cell lines. Int Immunol. 1999;11(8):1195-1202.
24. Rubin LA, Galli F, Greene WC, Nelson DL, Jay G. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine. 1990;2(5):330-336.
25. Tsukiyama-Kohara K, Iizuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol. 1992;66(3):1476-1483.
26. Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112(12):4384-4399.
27. el-Din HM, Attia MA, Hamza MR, Khaled HM, Thoraya MA, Eisa SA. Hepatitis C Virus and related changes in immunologic parameters in non Hodgkin's lymphoma patients. Egypt J Immunol. 2004;11(1):55-64.
28. Feldmann G, Nischalke HD, Nattermann J, et al. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12(15):4491-4498.
29. Mizuochi T, Ito M, Takai K, Yamaguchi K. Differential susceptibility of peripheral blood CD5+ and CD5- B cells to apoptosis in chronic hepatitis C patients. Biochem Biophys Res Commun. 2009;389(3):512-515.
30. Bansal AS, Bruce J, Hogan PG, Prichard P, Powell EE. Serum soluble CD23 but not IL8, IL10, GM-CSF, or IFN-gamma is elevated in patients with hepatitis C infection. Clin Immunol Immunopathol. 1997;84(2):139-144.
31. Barrett L, Gallant M, Howley C, et al. Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals. BMC Immunol. 2008;9:28. (Pubitemid 352003722)
32. Rubin LA, Kurman CC, Fritz ME, et al. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135(5):3172-3177.
33. Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120(12):1034-1041.
34. Stamataki Z, Shannon-Lowe C, Shaw J, et al. Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood. 2009;113(3):585-593.
35. Wasik MA, Sioutos N, Tuttle M, Butmarc JR, Kaplan WD, Kadin ME. Constitutive secretion of soluble interleukin-2 receptor by human T cell lymphoma xenografted into SCID mice. Correlation of tumor volume with concentration of tumor-derived soluble interleukin-2 receptor in body fluids of the host mice. Am J Pathol. 1994;144(5):1089-1097.
36. Tsai MH, Chiou SH, Chow KC. Effect of platelet activating factor and butyrate on the expression of interleukin-2 receptor alpha in nasopharyngeal carcinoma cells. Int J Oncol. 2001;19(5):1049-1055.
37. Yano T, Yoshino I, Yokoyama H, et al. The clinical significance of serum soluble interleukin-2 receptors in lung cancer. Lung Cancer. 1996;15(1):79-84.
38. Tesarova P, Kvasnicka J, Umlaufova A, Homolkova H, Jirsa M, Tesar V. Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit. 2000;6(4):661-667.
39. Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998;69(3):248-252.
40. Matsumoto T, Furukawa A, Sumiyoshi Y, Akiyama KY, Kanayama HO, Kagawa S. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma. Urology. 1998;51(1):145-149.
41. Pountain G, Hazleman B, Cawston TE. Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis. Br J Rheumatol. 1998;37(7):797-798.
42. Zekri AR, Alam El-Din HM, Bahnassy AA, et al. Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. Comp Hepatol. 2010:9(1):1.
43. Sheibani K, Winberg CD, van de Velde S, Blayney DW, Rappaport H. Distribution of lymphocytes with interleukin-2 receptors (TAC antigens) in reactive lymphoproliferative processes, Hodgkin's disease, and non-Hodgkin's lymphomas. An immunohistologic study of 300 cases. Am J Pathol. 1987;127(1):27-37.
44. Robb RJ, Rusk CM. High and low affinity receptors for interleukin 2: implications of pronase, phorbol ester, and cell membrane studies upon the basis for differential ligand affinities. J Immunol. 1986;137(1):142-149.
45. Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001;61(1):237-242.
46. Fluckiger AC, Garrone P, Durand I, Galizzi JP, Banchereau J. Interleukin 10 (IL-10) up-regulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes. J Exp Med. 1993;178(5):1473-1481.